Two distinct gut microbial pathways contribute to meta-organismal production of phenylacetylglutamine with links to cardiovascular disease

Recent studies show gut microbiota-dependent metabolism of dietary phenylalanine into phenylacetic acid (PAA) is critical in phenylacetylglutamine (PAGln) production, a metabolite linked to atherosclerotic cardio-vascular disease (ASCVD). Accordingly, microbial enzymes involved in this transformation are of interest. Us-ing genetic manipulation in selected microbes and monocolonization experiments in gnotobiotic mice, we identify two distinct gut microbial pathways for PAA formation; one is catalyzed by phenylpyruvate:ferre-doxin oxidoreductase (PPFOR) and the other by phenylpyruvate decarboxylase (PPDC). PPFOR and PPDC play key roles in gut bacterial PAA production via oxidative and non-oxidative phenylpyruvate decar-boxylation, respectively. Metagenomic analyses revealed a significantly higher abundance of both pathways in gut microbiomes of ASCVD patients compared with controls. The present studies show a role for these two divergent microbial catalytic strategies in the meta-organismal production of PAGln. Given the numerous links between PAGln and ASCVD, these findings will assist future efforts to therapeutically target PAGln for-mation in vivo.

Automated summary

Recent studies have shown the critical role of gut microbiota in metabolizing dietary phenylalanine into phenylacetic acid (PAA), which is important for the production of phenylacetylglutamine (PAGln) linked to atherosclerotic cardio-vascular disease (ASCVD). Researchers have identified two different microbial pathways, involving phenylpyruvate:ferre-doxin oxidoreductase (PPFOR) and phenylpyruvate decarboxylase (PPDC), for PAA formation in the gut. The abundance of these pathways is significantly higher in ASCVD patients compared to controls. These findings provide insights into the therapeutic targeting of PAGln formation in vivo.